Trials / Completed
CompletedNCT04318405
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Iron Isomaltoside 1000 in Patients With Iron Deficiency or Iron Deficiency Anemia: a Multicentric, Prospective, Longitudinal, Observational Study in Switzerland.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 327 (actual)
- Sponsor
- Pierre Fabre Pharma AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Real-CHOICE - designed as a prospective, longitudinal, observational, non-interventional study - will investigate the attitude of patients and physicians towards IV (intravenous) iron therapy in general and IIM (iron isomaltoside 1000) treatment particularly before and after IIM treatment in iron deficient patients with or without anemia in the real-world clinical setting after commercial availability of this product in Switzerland.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iron isomaltoside 1000 | Observation of real-life treatment with iron isomaltoside 1000 / Iron Derisomaltose 1000 |
Timeline
- Start date
- 2020-07-10
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
- First posted
- 2020-03-24
- Last updated
- 2023-07-19
Locations
21 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04318405. Inclusion in this directory is not an endorsement.